Skip to content

Enliven Therapeutics ELVN Proceeds from disposals of property, plant and equipment

Proceeds from disposals of property, plant and equipment at other companies

TE Connectivity logo
TE ConnectivityTEL
$3M+200%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$0-100%
Willis Lease Finance logo
Willis Lease FinanceWLFC
$71.41M+49.6%
Johnson Controls International logo
Johnson Controls InternationalJCI
$9.25M+3,600%
O'Reilly Automotive logo
O'Reilly AutomotiveORLY
$1.54M-20.8%
NXP Semiconductors logo
NXP SemiconductorsNXPI
$0-100%

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$3.47B+143%
Enterprise value$3.34B+156%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Enliven Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's proceeds from disposals of property, plant and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enliven Therapeutics's proceeds from disposals of property, plant and equipment?
Enliven Therapeutics (ELVN) reported proceeds from disposals of property, plant and equipment of $53.25K in Q4 2025.